Intranasal compositions

Details Intranasal compositions Intranasal compositions

2004-12-23

2011-10-11

Haghighatian, Mina (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S045000, C514S303000, C514S219000, C514S923000

Reexamination Certificate

active

08034371

ABSTRACT:
The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.

REFERENCES:
patent: 5655517 (1997-08-01), Coffee
patent: 6699849 (2004-03-01), Loftsson et al.
patent: 6713461 (2004-03-01), Billotte
patent: 7423026 (2008-09-01), Jarvinen et al.
patent: 2004/0176359 (2004-09-01), Wermeling
patent: 2004/0241100 (2004-12-01), Kramer et al.
patent: 2005/0215520 (2005-09-01), Liu et al.
patent: 0 681 833 (1995-11-01), None
patent: 1250925 (2002-04-01), None
patent: 98/30207 (1998-07-01), None
patent: 99/01498 (1999-01-01), None
patent: WO 03080021 (2003-10-01), None
patent: 03/095498 (2003-11-01), None
patent: 2004/067004 (2004-08-01), None
Illum, “Nasal drug delivery: new developments and Strategies”, Drug Discovery Today, vol. 7, No. 23, pp. 1184-1189, (2002).
Sweetman, “Martindale, The Complete Drug Reference”, Pharmaceutical Press, 33rd Edition, pp. 712-713, (2002).
Scrip, No. 2976, pp. 22, (2004).
Merck Index, No. 10321, pp. 1739.
Clauss et al., “Transient Improvement of Spinocerebellar Ataxia With Zolpidem”, New England Journal of Medicine, pp. 511-512, (2004).
Communication pursuant to Article 94(3) EPC, dated Apr. 7, 2008, in European Application No. 04 806 240.0, (related to U.S. Appl. No. 10/596,817) 5 pages.
Merkus et al., “Cyclodextrins in Nasel Drug Delivery”; Advaned Drug Delivery Reviews, 36th Edition, pp. 41-57, (1999).
Illum, “Nasel Delivery. The Use of Animal Models to Predict Performance in Man”; Journal of Drug Targeting, vol. 3, pp. 427-442 (1996).
Dollery, “Therapeutic Drugs”, Churchill Livingstone, 2nd Edition, pp. Z18-Z26, (1999).
Thompson, “Cyclodextrins Enabling Excipients: Their Present and Future Use in Pharmaceuticals”, Critical Reviews in Therapeutic Drug Carrier Systems, vol. 14, pp. 1-104, (1997).
Florence et al., “Physicochemical Principles of Pharmacy”, Macmillan, London, 3rd Edition, pp. 357-360, (1998).
Martin et al., “Physical Chemical Principles in the Pharmaceutical Sciences”, Physical Pharmacy, Fourth Edition, pp. 516-519, (1993).
Gennaro, “Remington: The Science and Practice of Pharmacy”, 20th Edition, Chapter 37, pp. 681-699, (2000).
Carstensen, “Pharmaceutical Principles of Solid Dosage Forms”, Technomic, pp. 15-31 & 95-104, (1993).

Affiliated with

Also associated with

Rating

Intranasal compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intranasal compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intranasal compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4260852